Claims
- 1. A method of alleviating symptoms of neuropathic conditions comprising the step of administering anti-glutamic acid decarboxylase (anti-GAD) antibody in an amount effective to alleviate symptoms of said neuropathic condition.
- 2. The method of claim 1, wherein the neuropathic conditions are selected from the group consisting of autism, multiple sclerosis, Parkinson's disease, attention deficit disorder, diabetic neuropathy and pain neuropathy associated with chemotherapy treatment.
- 3. The method of claim 1 wherein the anti-GAD antibodies are monoclonal antibodies.
- 4. The method of claim 1 wherein the administration step is oral.
- 5. The method of claim 4 wherein the administration step is sublingual.
- 6. The method of claim 4 wherein the anti-GAD antibodies are administered in an enterically protected form.
- 7. The method of claim 1 wherein the administration step is by injection.
- 8. The method of claim 7 wherein the administration step is by subcutaneous injection.
- 9. The method of claim 1 comprising less than 1.0 mg of anti-GAD antibodies.
- 10. The method of claim 9 comprising less than 1.0 μg of anti-GAD antibodies.
- 11. The method of claim 9 comprising from 1×10−6 to 1×10−2 μg of anti-GAD antibodies.
- 12. The method of claim 9 comprising from 1×10−5 to 1×10−2 μg of anti-GAD antibodies.
- 13. The method of claim 1, wherein the anti-GAD antibody is specific for GAD-65.
- 14. The method of claim 1, wherein the anti-GAD antibody is specific for GAD-67.
- 15. A pharmaceutical composition for administration to a subject for alleviating symptoms of neuropathic conditions comprising less than 1.0 mg of anti-GAD antibodies.
- 16. The pharmaceutical composition of claim 15 comprising less than 0.1 μg of anti-GAD antibodies.
- 17. The pharmaceutical composition of claim 15 comprising from 1×10−6 to 1×10−2 μg of anti-GAD antibodies.
- 18. The pharmaceutical composition of claim 15 comprising from 1×10−5 to 1×10−2 μg of anti-GAD antibodies.
- 19. The pharmaceutical composition of claim 15, wherein the antibodies are specific for GAD-65.
- 20. The pharmaceutical composition of claim 15, wherein the antibodies are specific for GAD-67.
Parent Case Info
[0001] This application is a continuation-in-part of U.S. application Ser. No 09/918,343 filed Jul. 30, 2001 and issued Aug. 20, 2002 as U.S. Pat. No. 6,436,401, which is a continuation-in-part of U.S. application Ser. No. 09/774,770 filed on Jan. 31, 2001 and issued Sep. 25, 2001 as U.S. Pat. No. 6,294,171, which is a continuation-in-part of U.S. application Ser. No. 09/514,993 filed on Feb. 29, 2000 and issued Feb. 13, 2001 as U.S. Pat. No. 6,187,309, which claims benefit of U.S. Provisional Application Serial No. 60/153,838 filed on Sep. 14, 1999; the disclosures of which are hereby incorporated by reference.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60153838 |
Sep 1999 |
US |
Continuation in Parts (3)
|
Number |
Date |
Country |
Parent |
09918343 |
Jul 2001 |
US |
Child |
10223498 |
Aug 2002 |
US |
Parent |
09774770 |
Jan 2001 |
US |
Child |
09918343 |
Jul 2001 |
US |
Parent |
09514993 |
Feb 2000 |
US |
Child |
09774770 |
Jan 2001 |
US |